SENL101 / Avalon GloboCare  >>  Phase 1
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
SENL101 / SenlangBio
NCT04572308: Cell Therapy for CD7 Positive T-cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Using CD7-Specific CAR-T Cells

Completed
1
20
RoW
CD7 CAR-T
Hebei Senlang Biotechnology Inc., Ltd.
T-cell Acute Lymphoblastic Leukemia/Lymphoma
05/21
05/21
NCT06136364: CD7 CAR-T in Adults With Relapsed or Refractory T-LBL/ALL Clinical Study

Recruiting
1
9
RoW
CAR-T
Hebei Senlang Biotechnology Inc., Ltd.
T-lymphoblastic Lymphoma, T-ALL
08/24
08/38
NCT05398614: SENL101 Autologous T Cell Injection in Adults With Relapsed or Refractory CD7+ Hematolymphoid Malignancies

Recruiting
1
18
RoW
SENL101
Hebei Senlang Biotechnology Inc., Ltd.
T-ALL, Lymphoma, T-Cell
12/23
06/24

Download Options